Get the Stockscreener App
162.94
0.18%
0.305
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $162.94, with a volume of 185.02K.
It is up +0.18% in the last 24 hours and up +6.05% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$162.64
Open:
$163
24h Volume:
185.02K
Relative Volume:
0.22
Market Cap:
$17.99B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
21.90
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
-0.10%
1M Performance:
+6.05%
6M Performance:
+11.50%
1Y Performance:
+27.88%
1-Day Range:
$161.71
$163.35
1-Week Range:
$160.01
$166.00
52-Week Range:
$123.30
$167.08
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
162.94 | 17.99B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
572.61 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.65 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.83 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
459.15 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
208.16 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
GHP Investment Advisors Inc. Increases Stake in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics (NYSE:DGX) Receives "Neutral" Rating from Piper Sandler - MarketBeat
JPMorgan Chase & Co. Increases Quest Diagnostics (NYSE:DGX) Price Target to $180.00 - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Position Boosted by Boston Trust Walden Corp - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Pacer Advisors Inc. - MarketBeat
YANKCOM Partnership Makes New Investment in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics (NYSE:DGX) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
Quest Diagnostics: Enhanced Offerings In Cardiometabolic Testing & Autoimmune Disorders Catalyzing Growth! - Smartkarma
Martin Capital Partners LLC Cuts Stake in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
3,910 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Bought by Jericho Financial LLP - MarketBeat
Hager Investment Management Services LLC Purchases New Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
UBS Group Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) Stock - Defense World
abrdn plc Reduces Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Mizuho Increases Quest Diagnostics (NYSE:DGX) Price Target to $178.00 - Defense World
Quest Diagnostics (NYSE:DGX) Price Target Raised to $170.00 at UBS Group - MarketBeat
Robeco Institutional Asset Management B.V. Sells 7,204 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest’s (NYSE:DGX) Q4: Beats On Revenue - Yahoo Finance
Quest Diagnostics Incorporated (NYSE:DGX) Sees Large Growth in Short Interest - MarketBeat
Preimplantation Genetic Testing Market to reach Blatant Growth - openPR
Quest Diagnostics (NYSE:DGX) Given New $182.00 Price Target at Truist Financial - MarketBeat
KBC Group NV Has $4.74 Million Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Announces Quarterly Dividend of $0.80 - MarketBeat
Mizuho Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
Piper Sandler Adjusts Price Target on Quest Diagnostics to $180 From $165 -February 03, 2025 at 11:34 am EST - Marketscreener.com
UBS Adjusts Price Target on Quest Diagnostics to $170 From $166, Maintains Neutral Rating - Marketscreener.com
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - Yahoo Finance
Quest Diagnostics Reports Strong Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases DividendSECAUCUS, N.J., January 30, 2025 — Quest Diagnostics Incorporated (NYSE: DGX) has recently announced it - Defense World
Quest Diagnostics (NYSE:DGX) Hits New 1-Year High After Strong Earnings - MarketBeat
Quest Diagnostics (NYSE:DGX) Price Target Raised to $175.00 - Defense World
Manning & Napier Advisors LLC Has $3.88 Million Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics (NYSE:DGX) Rating Increased to Buy at StockNews.com - MarketBeat
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.80 - Yahoo Finance
Copeland Capital Management LLC Has $30.07 Million Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Forsta AP Fonden Trims Stake in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Stock Position Lifted by Janney Montgomery Scott LLC - Defense World
Kingswood Wealth Advisors LLC Sells 1,970 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2024 Earnings Call Transcript - MSN
Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Grows - MSN
BankPlus Wealth Management LLC Takes $355,000 Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Earnings call transcript: Quest Diagnostics Q4 2024 beats EPS forecast - MSN
Mizuho lifts Quest Diagnostics target to $178 on strong outlook - MSN
What 6 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga
Quest Diagnostics (NYSE:DGX) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Mizuho Securities Adjusts Quest Diagnostics Price Target to $178 From $177, Maintains Outperform Rating - Marketscreener.com
Truist Securities Adjusts Quest Diagnostics Price Target to $182 From $172 -January 31, 2025 at 10:19 am EST - Marketscreener.com
Evercore ISI Adjusts Quest Diagnostics Price Target to $175 From $160 -January 31, 2025 at 10:19 am EST - Marketscreener.com
Barclays Adjusts Quest Diagnostics Price Target to $175 From $168 -January 31, 2025 at 10:18 am EST - Marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $189 From $184 -January 31, 2025 at 10:18 am EST - Marketscreener.com
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results, Provides Guidance for Full Year 2025, Increases Quarterly Dividend 6.7% to $0.80 per Share - Marketscreener.com
Quest Diagnostics Inc (DGX) Q4 2024 Earnings Call Highlights: St - GuruFocus.com
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.49%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):